CD274 and cancer: Programmed cell death ligand 1 (PD-L1), programmed cell death protein 1 (PD-1), and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) blockade have emerged in the past decade, representing a paradigm shift in cancer care (Campbell et al., 2016).